Received May 8, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | NM99E | — |
Patient received only the sterile water (diluent) of the Arexvy vaccine/Maladministration of diluent only (Inappropriate reconstitution technique); Patient received only the sterile water (diluent) of the Arexvy vaccine/Maladministration of diluent only (Inappropriate reconstitution technique); This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received RSVPreF3 adjuvanted (Arexvy) (batch number NM99E, expiry date 23-JAN-2027) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced inappropriate preparation of medication (Verbatim: Patient received only the sterile water (diluent) of the Arexvy vaccine/Maladministration of diluent only (Inappropriate reconstitution technique)) and inappropriate dose of vaccine administered (Verbatim: Patient received only the sterile water (diluent) of the Arexvy vaccine/Maladministration of diluent only (Inappropriate reconstitution technique)). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 01-MAY-2026 The suspect vaccine start dates ranges from 03-DEC-2025 to 16-MAR-2026. The batch number was not provided and a request for this information has been made. This case has been linked to the case US2026059875 reported by the same reporter.; Sender's Comments: US-GSK-US2026059875:Same reporter